Connect with us

4 Top Fintech Stocks To Watch This Week

Could fintech stocks be worth a look at their current price points?
The post 4 Top Fintech Stocks To Watch This Week appeared first on Stock Market News,…

Published

on

Do You Have These Fintech Stocks On Your Watchlist?

Fintech stocks have gained popularity in the stock market over the past few years as adoption increases. For obvious reasons, the global pandemic played a significant role in the industry’s growth. Contactless payment options were deemed a necessity and consumers are noticing the convenience that comes along with it. However, with expectations of post-pandemic slowdown and rising interest rates, this segment of the market has been under tremendous pressure in recent months. In fact, many fintech stocks are returning to their pre-pandemic levels. As such, prospective investors are likely looking at the industry’s long-term potential for growth. With that said, some of the top names in the industry today may start to look attractive at their current valuations. 

Many may be focusing on the likes of Visa (NYSE: V) and Fiserv (NASDAQ: FISV) which are reporting their financials later this week. A strong financial showing from these top fintech companies will likely set the tone for the industry. Fiserv also recently announced a partnership with Equifax (NYSE: EFX) to deliver data-driven insights that organizations need to succeed in a digital economy. As a result, companies will get a more holistic picture of businesses and allow them to embrace the power of real-time data insights. If you believe that fintech will continue to define the industry landscape, here are some of the top fintech stocks to check out in the stock market today.

Fintech Stocks To Watch This Week

Block

Block, formerly known as Square, is a tech company that specializes in financial services. The company provides tools to help the community to access the economy. It does so by helping sellers run and grow their businesses with its integrated ecosystem for commerce, business software, and banking services. Besides that, its Cash App allows anyone to send, spend, or invest their money in stocks or Bitcoin. 

Last month, the company announced a partnership with CodeBase. The collaboration with one of the U.K.’s largest tech start-ups aims to provide entrepreneurs with access to Square’s payment ecosystem and Application Programming Interfaces. Therefore, the company will support CodeBase by offering a series of workshops that enable entrepreneurs to learn from leaders in the commerce and payments industry. Not to mention, the start-ups will have full access to Square’s platform team for any questions and support throughout the process. All things considered, would you bank on the future of SQ stock?

SQ stock chart
Source: TD Ameritrade TOS

[Read More] Stock Market Today: Dow Jones, S&P 500 Opened In The Red; Twitter Takeover Reportedly In The Works

Mastercard

Another goliath in the fintech industry today is Mastercard. Known for its Mastercard brand debit, credit, and prepaid cards, the company is no stranger to most. As of April, the company has been actively collaborating with others to expand its growth. For starters, it formed a new partnership with Interos, a hyper-growth operational resilience company. The partnership aims to expand its security strategy and bring Interos’ multi-tier risk monitoring capabilities to financial institutions. Therefore, the new offering can allow organizations to proactively detect and eliminate risk throughout their network of business. 

A more recent partnership was sealed with Nelo last week. For those unaware, Nelo is a Buy Now Pay Later (BNPL) product in Mexico. With this new partnership, Nelo announced the launch of its all-in-one app. So, customers of Nelo can now use Nelo at any online merchant within the Mastercard network. This makes Nelo the first company in Latin America to offer a mobile app that provides such functionality. All in all, these are all encouraging developments for Mastercard as it continues to grow on the right trajectory. With that in mind, could MA stock be a top fintech stock to watch right now?

MA stock chart
Source: TD Ameritrade TOS

PayPal

In many ways, PayPal is similar to our previous entries as its product and services are used by people around the world. Essentially, this is a fintech that enables digital payments and commerce experiences on behalf of merchants and consumers across the globe. Some of its notable brands include PayPal, Venmo, Braintree, Honey, Xoom, and Happy Returns by PayPal. Investors should note that the company will be announcing its earnings later this week. As such, it should not be surprising that there will be more attention on the company stock right now. 

Despite PYPL stock’s performance over the past year, many would argue that it still boasts a strong recovery potential long-term. After all, PayPal still consistently innovates to provide the best for its customers. We saw the company announcing the introduction of its PayPal Cashback credit card earlier this month. The card is issued by Synchrony and gives customers, even more, cashback when they shop with PayPal. What’s more, customers can earn unlimited 3% cashback regardless of the categories they spend on that month. Considering these exciting new products, would you be adding PYPL stock to your watchlist? 

PYPL stock chart
Source: TD Ameritrade TOS

[Read More] Top Stock Market News For Today April 25, 2022

Affirm 

Finally, we will be looking at the fintech giant, Affirm. In detail, the company operates a platform for digital and mobile-first commerce in North America. Its platform includes point-of-sale payment solutions for consumers, merchant commerce solutions, and a consumer-focused app. Thus, consumers can pay for a purchase over time via its payment network and partnerships with banks. Much like most fintechs in the stock market today, the year 2022 has been a struggle for AFRM stock. That said, investors eyeing the stock could be looking to buy the stock on dips. 

In fact, Affirm recently announced an expansion of its partnership with Poshmark (NASDAQ: POSH). The two-year extension aims to deliver increased payment flexibility to shoppers. Hence, eligible shoppers from Poshmark’s community can now choose between monthly payments or four interest-free payments every other week for all items that cost over $50. On a sense of scale, Affirm will have access to more than 80 million users from Poshmark’s community. This is important for the growth of any company as it gains access to more consumers. So, should you keep a closer watch on AFRM stock?

AFRM stock
Source: TD Ameritrade TOS

If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!

The post 4 Top Fintech Stocks To Watch This Week appeared first on Stock Market News, Quotes, Charts and Financial Information | StockMarket.com.

Read More

Continue Reading

International

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever… And Debt Explodes

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever… And Debt Explodes

Earlier today, CNBC’s…

Published

on

US Spent More Than Double What It Collected In February, As 2024 Deficit Is Second Highest Ever... And Debt Explodes

Earlier today, CNBC's Brian Sullivan took a horse dose of Red Pills when, about six months after our readers, he learned that the US is issuing $1 trillion in debt every 100 days, which prompted him to rage tweet, (or rageX, not sure what the proper term is here) the following:

We’ve added 60% to national debt since 2018. Germany - a country with major economic woes - added ‘just’ 32%.   

Maybe it will never matter.   Maybe MMT is real.   Maybe we just cancel or inflate it out. Maybe career real estate borrowers or career politicians aren’t the answer.

I have no idea.  Only time will tell.   But it’s going to be fascinating to watch it play out.

He is right: it will be fascinating, and the latest budget deficit data simply confirmed that the day of reckoning will come very soon, certainly sooner than the two years that One River's Eric Peters predicted this weekend for the coming "US debt sustainability crisis."

According to the US Treasury, in February, the US collected $271 billion in various tax receipts, and spent $567 billion, more than double what it collected.

The two charts below show the divergence in US tax receipts which have flatlined (on a trailing 6M basis) since the covid pandemic in 2020 (with occasional stimmy-driven surges)...

... and spending which is about 50% higher compared to where it was in 2020.

The end result is that in February, the budget deficit rose to $296.3 billion, up 12.9% from a year prior, and the second highest February deficit on record.

And the punchline: on a cumulative basis, the budget deficit in fiscal 2024 which began on October 1, 2023 is now $828 billion, the second largest cumulative deficit through February on record, surpassed only by the peak covid year of 2021.

But wait there's more: because in a world where the US is spending more than twice what it is collecting, the endgame is clear: debt collapse, and while it won't be tomorrow, or the week after, it is coming... and it's also why the US is now selling $1 trillion in debt every 100 days just to keep operating (and absorbing all those millions of illegal immigrants who will keep voting democrat to preserve the socialist system of the US, so beloved by the Soros clan).

And it gets even worse, because we are now in the ponzi finance stage of the Minsky cycle, with total interest on the debt annualizing well above $1 trillion, and rising every day

... having already surpassed total US defense spending and soon to surpass total health spending and, finally all social security spending, the largest spending category of all, which means that US debt will now rise exponentially higher until the inevitable moment when the US dollar loses its reserve status and it all comes crashing down.

We conclude with another observation by CNBC's Brian Sullivan, who quotes an email by a DC strategist...

.. which lays out the proposed Biden budget as follows:

The budget deficit will growth another $16 TRILLION over next 10 years. Thats *with* the proposed massive tax hikes.

Without them the deficit will grow $19 trillion.

That's why you will hear the "deficit is being reduced by $3 trillion" over the decade.

No family budget or business could exist with this kind of math.

Of course, in the long run, neither can the US... and since neither party will ever cut the spending which everyone by now is so addicted to, the best anyone can do is start planning for the endgame.

Tyler Durden Tue, 03/12/2024 - 18:40

Read More

Continue Reading

Government

Buried Project Veritas Recording Shows Top Pfizer Scientists Suppressed Concerns Over COVID-19 Boosters, MRNA Tech

Buried Project Veritas Recording Shows Top Pfizer Scientists Suppressed Concerns Over COVID-19 Boosters, MRNA Tech

Submitted by Liam Cosgrove

Former…

Published

on

Buried Project Veritas Recording Shows Top Pfizer Scientists Suppressed Concerns Over COVID-19 Boosters, MRNA Tech

Submitted by Liam Cosgrove

Former Project Veritas & O’Keefe Media Group operative and Pfizer formulation analyst scientist Justin Leslie revealed previously unpublished recordings showing Pfizer’s top vaccine researchers discussing major concerns surrounding COVID-19 vaccines. Leslie delivered these recordings to Veritas in late 2021, but they were never published:

Featured in Leslie’s footage is Kanwal Gill, a principal scientist at Pfizer. Gill was weary of MRNA technology given its long research history yet lack of approved commercial products. She called the vaccines “sneaky,” suggesting latent side effects could emerge in time.

Gill goes on to illustrate how the vaccine formulation process was dramatically rushed under the FDA’s Emergency Use Authorization and adds that profit incentives likely played a role:

"It’s going to affect my heart, and I’m going to die. And nobody’s talking about that."

Leslie recorded another colleague, Pfizer’s pharmaceutical formulation scientist Ramin Darvari, who raised the since-validated concern that repeat booster intake could damage the cardiovascular system:

None of these claims will be shocking to hear in 2024, but it is telling that high-level Pfizer researchers were discussing these topics in private while the company assured the public of “no serious safety concerns” upon the jab’s release:

Vaccine for Children is a Different Formulation

Leslie sent me a little-known FDA-Pfizer conference — a 7-hour Zoom meeting published in tandem with the approval of the vaccine for 5 – 11 year-olds — during which Pfizer’s vice presidents of vaccine research and development, Nicholas Warne and William Gruber, discussed a last-minute change to the vaccine’s “buffer” — from “PBS” to “Tris” — to improve its shelf life. For about 30 seconds of these 7 hours, Gruber acknowledged that the new formula was NOT the one used in clinical trials (emphasis mine):


“The studies were done using the same volume… but contained the PBS buffer. We obviously had extensive consultations with the FDA and it was determined that the clinical studies were not required because, again, the LNP and the MRNA are the same and the behavior — in terms of reactogenicity and efficacy — are expected to be the same.

According to Leslie, the tweaked “buffer” dramatically changed the temperature needed for storage: “Before they changed this last step of the formulation, the formula was to be kept at -80 degrees Celsius. After they changed the last step, we kept them at 2 to 8 degrees celsius,” Leslie told me.

The claims are backed up in the referenced video presentation:

I’m no vaccinologist but an 80-degree temperature delta — and a 5x shelf-life in a warmer climate — seems like a significant change that might warrant clinical trials before commercial release.

Despite this information technically being public, there has been virtually no media scrutiny or even coverage — and in fact, most were told the vaccine for children was the same formula but just a smaller dose — which is perhaps due to a combination of the information being buried within a 7-hour jargon-filled presentation and our media being totally dysfunctional.

Bohemian Grove?

Leslie’s 2-hour long documentary on his experience at both Pfizer and O’Keefe’s companies concludes on an interesting note: James O’Keefe attended an outing at the Bohemian Grove.

Leslie offers this photo of James’ Bohemian Grove “GATE” slip as evidence, left on his work desk atop a copy of his book, “American Muckraker”:

My thoughts on the Bohemian Grove: my good friend’s dad was its general manager for several decades. From what I have gathered through that connection, the Bohemian Grove is not some version of the Illuminati, at least not in the institutional sense.

Do powerful elites hangout there? Absolutely. Do they discuss their plans for the world while hanging out there? I’m sure it has happened. Do they have a weird ritual with a giant owl? Yep, Alex Jones showed that to the world.

My perspective is based on conversations with my friend and my belief that his father is not lying to him. I could be wrong and am open to evidence — like if boxer Ryan Garcia decides to produce evidence regarding his rape claims — and I do find it a bit strange the club would invite O’Keefe who is notorious for covertly filming, but Occam’s razor would lead me to believe the club is — as it was under my friend’s dad — run by boomer conservatives the extent of whose politics include disliking wokeness, immigration, and Biden (common subjects of O’Keefe’s work).

Therefore, I don’t find O’Keefe’s visit to the club indicative that he is some sort of Operation Mockingbird asset as Leslie tries to depict (however Mockingbird is a 100% legitimate conspiracy). I have also met James several times and even came close to joining OMG. While I disagreed with James on the significance of many of his stories — finding some to be overhyped and showy — I never doubted his conviction in them.

As for why Leslie’s story was squashed… all my sources told me it was to avoid jail time for Veritas executives.

Feel free to watch Leslie’s full documentary here and decide for yourself.

Fun fact — Justin Leslie was also the operative behind this mega-viral Project Veritas story where Pfizer’s director of R&D claimed the company was privately mutating COVID-19 behind closed doors:

Tyler Durden Tue, 03/12/2024 - 13:40

Read More

Continue Reading

International

Association of prenatal vitamins and metals with epigenetic aging at birth and in childhood

“[…] our findings support the hypothesis that the intrauterine environment, particularly essential and non-essential metals, affect epigenetic aging…

Published

on

“[…] our findings support the hypothesis that the intrauterine environment, particularly essential and non-essential metals, affect epigenetic aging biomarkers across the life course.”

Credit: 2024 Bozack et al.

“[…] our findings support the hypothesis that the intrauterine environment, particularly essential and non-essential metals, affect epigenetic aging biomarkers across the life course.”

BUFFALO, NY- March 12, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 16, Issue 4, entitled, “Associations of prenatal one-carbon metabolism nutrients and metals with epigenetic aging biomarkers at birth and in childhood in a US cohort.”

Epigenetic gestational age acceleration (EGAA) at birth and epigenetic age acceleration (EAA) in childhood may be biomarkers of the intrauterine environment. In this new study, researchers Anne K. Bozack, Sheryl L. Rifas-Shiman, Andrea A. Baccarelli, Robert O. Wright, Diane R. Gold, Emily Oken, Marie-France Hivert, and Andres Cardenas from Stanford University School of Medicine, Harvard Medical School, Harvard T.H. Chan School of Public Health, Columbia University, and Icahn School of Medicine at Mount Sinai investigated the extent to which first-trimester folate, B12, 5 essential and 7 non-essential metals in maternal circulation are associated with EGAA and EAA in early life. 

“[…] we hypothesized that OCM [one-carbon metabolism] nutrients and essential metals would be positively associated with EGAA and non-essential metals would be negatively associated with EGAA. We also investigated nonlinear associations and associations with mixtures of micronutrients and metals.”

Bohlin EGAA and Horvath pan-tissue and skin and blood EAA were calculated using DNA methylation measured in cord blood (N=351) and mid-childhood blood (N=326; median age = 7.7 years) in the Project Viva pre-birth cohort. A one standard deviation increase in individual essential metals (copper, manganese, and zinc) was associated with 0.94-1.2 weeks lower Horvath EAA at birth, and patterns of exposures identified by exploratory factor analysis suggested that a common source of essential metals was associated with Horvath EAA. The researchers also observed evidence of nonlinear associations of zinc with Bohlin EGAA, magnesium and lead with Horvath EAA, and cesium with skin and blood EAA at birth. Overall, associations at birth did not persist in mid-childhood; however, arsenic was associated with greater EAA at birth and in childhood. 

“Prenatal metals, including essential metals and arsenic, are associated with epigenetic aging in early life, which might be associated with future health.”

 

Read the full paper: DOI: https://doi.org/10.18632/aging.205602 

Corresponding Author: Andres Cardenas

Corresponding Email: andres.cardenas@stanford.edu 

Keywords: epigenetic age acceleration, metals, folate, B12, prenatal exposures

Click here to sign up for free Altmetric alerts about this article.

 

About Aging:

Launched in 2009, Aging publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at www.Aging-US.com​​ and connect with us:

  • Facebook
  • X, formerly Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Reddit
  • Pinterest
  • Spotify, and available wherever you listen to podcasts

 

Click here to subscribe to Aging publication updates.

For media inquiries, please contact media@impactjournals.com.

 

Aging (Aging-US) Journal Office

6666 E. Quaker Str., Suite 1B

Orchard Park, NY 14127

Phone: 1-800-922-0957, option 1

###


Read More

Continue Reading

Trending